Promius Pharma announced that Zembrace SymTouch, indicated to treat acute migraine headaches with or without aura in adults, is now commercially available in the U.S.
Zembrace SymTouch contains 3mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The product comes as a prefilled, low-dose, ready-to-use, disposable autoinjector, and each box contains 4 autoinjectors. The 3mg dose, administered subcutaneously, allows for more dosing flexibility as patients can use up to 4 doses in a 24-hour period.
Sumatriptan is a selective 5-HT 1B/1D receptor agonist. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist production at the 5-HT1B/1D receptors, at the intracranial blood vessels and sensory nerves of the trigeminal system. This results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
The most common side effects are pain and redness at the injection site; tingling or numbness in your fingers or toes; dizziness; warm hot burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired.
For more information call (609) 282-1400 or visit Zembrace.com.